At the heart of precision oncology lies the integration of various disciplines, including genomics, molecular biology, bioinformatics and clinical research. Blood cancers, including acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML) and myeloproliferative neoplasms (MPNs), pose unique challenges in diagnosis and treatment. However, with the rapid advancements in precision medicine, there is renewed hope for more effective and personalised approaches to managing these diseases.
In this webinar series, we will explore cutting-edge developments and breakthroughs in precision oncology. We will explore the latest research, innovative therapies and diagnostic tools that are revolutionising the way we understand and combat these complex conditions.
Join us as leading experts in the field share their knowledge, experiences and insights into precision oncology, shedding light on the potential benefits it holds for patients and on the future of blood cancer treatment. Whether you are a healthcare professional or a researcher seeking the latest information, this series will provide you with invaluable updates and perspectives on the evolving landscape of precision oncology.
**Please note, by registering for the first webinar in the series you will automatically gain access to all subsequent webinars in the series**
This webinar is CPD accredited.
– – – – –
Tuesday 6th June at 3pm BST / 4pm CET / 10am EST
Acute myeloid leukaemia (AML) is the predominant form of acute leukaemia among adults. It is characterised by rapid progression and necessitates prompt intervention. The purpose of this webinar is to assess the current state of precision medicine and immunotherapy in AML, emphasising avenues for enhancing diagnostic and treatment approaches. Moreover, it will highlight the advantages that patients can presently derive from these advancements as well as their potential future benefits.
- Talk Title: New Insights in NPM1-mutated AML
- Brunangelo Falini, Head of the Institute of Haematology and Bone Marrow Transplantation, University and Hospital of Perugia
- Talk title: Car-T in AML Challenges and Perspectives
- Andrea Biondi, Professor, University of Milano-Bicocca
– – – – –
Tuesday 13th June at 3pm BST / 4pm CET / 10am EST
Chronic myeloid leukaemia (CML) is a blood cancer characterised by a gradual growth rate that spans several years. When detected at an early stage the prognosis for a 5-year survival is generally favourable. Moreover, precision medicine presents novel possibilities for prolonging this life expectancy. This webinar will cover the advances in precision medicine for CML as well as their implementation in the clinic.
- Talk title: Trends and Opportunities in the Treatment of CML
- Gillian Horne, Clinical Senior Research Fellow, Paul O’Gorman Leukaemia Research Centre, University of Glasgow
- Talk title: Clinical Diagnostic Testing in CML: Current Methods of Diagnosis and Management
- Robert Dunn, Head of Cytogenetics, King’s College Hospital NHS Foundation Trust
- Talk title: Updates on the Management of Chronic Myeloid Leukaemia
- Fadi G. Haddad, Assistant Professor, The University of Texas MD Anderson Cancer Center
– – – – –
Tuesday 20th June at 3 pm BST/4 pm CET/10 am EST
Myeloproliferative neoplasms (MPNs) encompass a collection of uncommon blood disorders. While officially categorised as blood cancers by the World Health Organization (WHO), individuals with MPNs frequently experience a relatively good state of well-being, and the prognosis may differ based on the rate of disease advancement. This webinar will explore the precision medicine and immunotherapy strategies available for addressing MPNs.
- Talk title: Momelotinib: The Case for a 4th JAK Inhibitor
- Aaron T. Gerds, MD, Associate Professor of Medicine, Haematology & Medical Oncology, Deputy Director for Clinical Research, Cleveland Clinic Taussig Cancer Institute
- Talk title: Novel Immunotherapy Strategies for Myeloproliferative Neoplasms
- Cansu Cimen Bozkus, Assistant Professor, Icahn School of Medicine at Mount Sinai
– – – – –
This webinar series is kindly sponsored by: